ReShape Lifesciences Inc.
RSLS
$0.365
-$0.015-3.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -3.71% | 55.26% | 54.34% | 17.62% | 89.69% |
| Total Depreciation and Amortization | -28.57% | -90.00% | -87.76% | -87.50% | -98.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8,020.00% | -71.58% | 76.36% | 85.88% | -100.04% |
| Change in Net Operating Assets | 188.44% | 560.09% | 108.30% | 1,065.96% | -174.53% |
| Cash from Operations | 72.04% | 88.81% | 79.63% | 59.06% | 13.15% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -98.93% | -- | 702.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -88.04% | 100.00% | -98.93% | -- | 755.96% |
| Foreign Exchange rate Adjustments | -366.67% | -- | 800.00% | -60.00% | 130.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -101.66% | 90.06% | 69.97% | -140.56% | 231.44% |